Tsubota Laboratory (4890) · TargetSoftened
Commercialization of Medical Devices by ケラバイオ
First written in FY2022. 1 of 3 entries say "Advanced", first in FY2023. Latest entry: FY2024.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Commercialization of ophthalmic pharmaceuticals and medical devicesA theme 7 companies write about · 0 as a headwind · 10 as a tailwind
Tsubota Laboratory moved to the "Worse" side of this theme in 2024.
The whole theme swung hardest in 2024: 1 of 7 companies on the "Worse" side.
0 other companies' latest entry also says "Softened".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2024SoftenedAnnual report
「The specified clinical research on TLG-003, a therapeutic device for keratoconus, has ended, and the company is considering its future development policy.」
The specified clinical research on TLG-003 has ended, but no specific next step toward launch has been indicated, and the company is considering its future development policy. - FY2023AdvancedAnnual report
「The company has conducted exploratory clinical research combining TLG-003 use with riboflavin eye drops and confirmed favorable efficacy and safety.」
ケラバイオ completed exploratory clinical research and confirmed safety and efficacy. It is preparing clinical trials and establishing the necessary stakeholder framework for the launch of the medical device. - FY2022First statedAnnual report
「The company is currently preparing clinical trials and establishing the necessary stakeholder framework to launch TLG-003 as a medical device.」
Following confirmation of safety and efficacy in exploratory clinical research, the company aims to launch it as a minimally invasive therapeutic device that does not require eye drops.